Synthekine Trial Shows New Hope for Advanced Tumor Battles
Synthekine Inc., a leader in engineered cytokine therapeutics, has announced promising initial findings from a Phase 1a/1b trial of...
Denovo Biopharma’s Revelation: Precision Treatment for Depression’s Grip
Denovo Biopharma’s Phase 2b ENLIGHTEN trial has demonstrated the efficacy and safety of liafensine (DB104) in treating treatment-resistant depression...
Pfizer’s Abrysvo® Triumphs in Phase 3 Study for RSV Prevention
Pfizer announced promising results from a Phase 3 study of its respiratory syncytial virus (RSV) vaccine, ABRYSVO. The study...
ViiV’s Dolutegravir/Lamivudine FDA Approved for HIV-Positive Adolescents
The U.S. Food and Drug Administration (FDA) has approved the use of Dovato for treating HIV-1 infection in adolescents...
Boundless Bio Unveils Preclinical and Clinical Data on ecdna-Directed BBI-355
Boundless Bio presents findings from preclinical and clinical studies of BBI-355, a novel inhibitor of checkpoint kinase 1 (CHK1),...
Alterome Uncovers Pre-Clinical Data for Lead AKT1 E17K Inhibitor Program Development
Alterome Therapeutics has developed ALTA-2618, a potent and selective covalent inhibitor targeting the AKT1 E17K mutation found in various...
AltPep Study in Nature Journal Affirms Potential of Blood Test for Alzheimer’s Detection
AltPep Corporation’s SOBA-AD blood test has demonstrated promising accuracy in detecting Alzheimer’s diseaseAlzheimer’s disease (AD) in two independent studies....
Bristol Myers Squibb & 2Seventy Abecma Expands Approval for Multiple Myeloma Treatment
Abecma, a personalized CAR T cell therapy, has received expanded approval from the FDA for the treatment of adult...
Alnylam Unveils Positive KARDIA-2 Phase 2 Results for Zilebesiran in Hypertensive Patients
The KARDIA-2 Phase 2 study evaluated the efficacy and safety of zilebesiran, an RNAi therapeutic targeting hypertension, when added...
Merck Launches Phase 3 Trial with Combo of MK-1084 & KeytrudaⓇ for NSCLC Treatment
Merck has initiated a Phase 3 clinical trial (NCT06345729) to evaluate MK-1084, an oral KRAS G12C inhibitor, in combination...